Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesEKF Diagnostics Holdings Plc

EKF Diagnostics Holdings Plc

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
24.4 GBX -0.40 ( 1.61%)
Last update at 2026-10-27T16:37:00Z
VOLUME
204049
Market Cap
104.15M

Momentum Score

…

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab HbA1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test HbA1c, fully automated hemoglobin A1c analyzer for the monitoring and management of diabetes; and STAT-Site W Beta-Hydroxybutyrate analyzer. In addition, the company offers Creamatocrit Plus, a breast milk analyzer; QuPID and True20 pregnancy tests; Lactate Scout Vet, a handheld lactate analyzer for veterinary care; Hemo Vet, a point-of-care hemoglobin and hematocrit analyzer; Lactate Scout Sport, a lactate analyzer for sports performance; Biosen series for sports; and EKF Link, a data management solution that integrates point-of-care analyzers. Further, it offers Beta-Hydroxybutyrate LiquiColor for monitoring ketosis; RaPET, a range of immunoassay kits; QuStick Strep A for Strep A infection treatment; Hema-Screen Lab Pack for detection of colorectal cancer; PrimeStore MTM, a molecular transport medium that preserves and stabilizes DNA and RNA; Uri-Trak 120M urine analyzer; and clinical chemistry reagents, controls, and standards. Additionally, the company provides precision fermentation, custom bioprocessing, and contract manufacturing solutions; and diagnostic enzymes that include arylacylamidase, beta-hydroxybutyrate dehydrogenase, and salicylate hydroxylase. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
24.00
Low
24.90
High
52 Week Price Range
19.00
Low
32.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

EKF Diagnostics Holdings plc manufactures and distributes in vitro diagnostic instruments, reagents and point-of-care tests for clinical and industrial customers worldwide. Long-term growth may be supported by rising demand for decentralized and chronic-disease testing, recurring consumable sales and expansion into emerging markets, and the company appears positioned to benefit from a diversified product portfolio and recurring revenue streams.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
24.80
Dividend Yield
-
Revenue TTM
51.56M
Revenue Per Share
0.12
Gross Profit TTM
26.48M
Debt / Equity
0.02
ROE
3.53%
Net Debt
-14.45M
ROCE
9.15%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 7.09M 6.26M 2.13M -8.94M 21.43M
Minority interest - -0.34M -0.38M -0.53M -0.31M
Net income 2.12M 6.24M 2.35M -9.58M 15.85M
Selling general administrative - 18.08M 19.68M 23.18M 17.71M
Selling and marketing expenses - - 1.80M - -
Gross profit 26.48M 21.48M 23.86M 24.04M 39.37M
Reconciled depreciation - 4.72M 5.47M 6.66M 5.88M
Ebit - 6.43M 2.21M 1.91M 21.75M
Ebitda 6.75M 11.16M 7.68M 8.57M 27.68M
Depreciation and amortization - 4.72M 5.47M 6.66M 5.93M
Operating income 6.75M 6.46M 2.08M 1.91M 21.75M
Other operating expenses 44.82M 43.93M 50.53M 64.86M 60.09M
Interest expense 0.15M 0.17M 0.07M 0.10M 0.36M
Tax provision - -0.31M -0.60M 0.63M 5.28M
Interest income - 0.17M 0.12M 0.13M 0.04M
Net interest income - 0.00M 0.05M 0.03M -0.31M
Income tax expense 4.55M -0.31M -0.60M 0.63M 5.28M
Total revenue 51.56M 50.19M 52.61M 66.64M 81.84M
Total operating expenses 19.73M 15.02M 21.78M 22.26M 17.62M
Cost of revenue 25.08M 28.71M 28.75M 42.60M 42.47M
Total other income expense net 0.34M -0.20M 0.05M -10.85M -0.31M
Net income from continuing ops - 6.58M 2.73M -9.58M 16.16M
Net income applicable to common shares - - - -10.10M 15.85M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 81.14M 81.75M 80.85M 89.29M 115.12M
Intangible assets 3.75M 5.05M 5.80M 8.65M 14.51M
Other current assets - 1.87M 4.54M -0.01M 13.98M
Total liab 10.86M 8.53M 12.63M 14.77M 20.38M
Total stockholder equity 69.05M 72.33M 67.12M 73.35M 94.12M
Deferred long term liab - - - 3.96M 3.44M
Other current liab 1.69M 4.70M 4.53M 2.44M 0.47M
Common stock 4.34M 4.54M 4.54M 4.55M 4.64M
Capital stock - 4.54M 4.54M 4.55M 4.64M
Retained earnings 52.14M 55.00M 48.76M 52.46M 74.26M
Other liab - - - 2.49M 5.20M
Good will 24.14M 23.88M 24.43M 25.12M 27.38M
Other assets - - - 4.88M 0.01M
Cash 15.83M 14.30M 6.02M 11.58M 20.34M
Total current liabilities 7.42M 6.44M 9.50M 11.74M 13.65M
Current deferred revenue - - - - 3.00M
Net debt -14.45M -12.98M -1.92M -10.03M -17.71M
Short term debt 0.40M 0.84M 3.48M 1.01M 1.10M
Short long term debt - 0.00M 2.99M 0.14M 0.27M
Short long term debt total 1.39M 1.32M 4.10M 1.55M 2.63M
Other stockholder equity 7.44M 7.39M 7.39M 16.34M 15.22M
Property plant equipment - - - 21.71M 17.87M
Total current assets 30.88M 28.55M 25.56M 31.76M 47.55M
Net tangible assets - - - 43.53M 52.23M
Short term investments - -1.29M - - -
Net receivables 6.74M 6.28M 6.23M 10.76M 13.98M
Long term debt - 0.00M 0.00M 0.00M 0.43M
Inventory 8.30M 7.39M 8.77M 9.43M 13.24M
Accounts payable 5.33M 0.90M 0.98M 8.29M 9.08M
Accumulated other comprehensive income 5.12M 5.40M 6.44M - -
Non currrent assets other - 0.23M 0.28M 1.12M 7.79M
Non current assets total 50.26M 53.19M 55.29M 57.53M 67.56M
Capital lease obligations - 1.32M 1.11M 1.41M 1.93M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -2.66M -5.64M -8.93M -5.48M
Change to liabilities - - - -2.18M 1.22M
Total cashflows from investing activities -2.34M -2.66M -5.64M -8.93M -5.48M
Net borrowings - -3.00M 2.86M -1.68M -0.82M
Total cash from financing activities -5.86M -4.08M -3.65M -11.04M -6.16M
Net income 2.12M 6.24M 2.13M -8.94M 21.43M
Change in cash 1.53M 6.58M -3.85M -8.76M -1.57M
Begin period cash flow 14.30M 7.73M 11.58M 20.34M 21.91M
End period cash flow 15.83M 14.30M 7.73M 11.58M 20.34M
Total cash from operating activities 9.71M 13.66M 6.31M 9.69M 10.24M
Issuance of capital stock - - - - 0.00M
Depreciation - 4.72M 5.47M 6.66M 5.88M
Other cashflows from investing activities - -0.42M -0.38M - 0.04M
Dividends paid - - 5.45M 5.46M 5.10M
Change to inventory - 0.77M -0.74M -0.81M -4.60M
Change to account receivables - -0.12M 2.50M 1.28M -3.27M
Sale purchase of stock - - 0.00M -3.90M -
Other cashflows from financing activities -0.87M -1.08M -1.06M -1.07M -0.87M
Change to netincome - - - 14.85M -4.84M
Capital expenditures 1.53M 2.25M 6.97M 5.83M 5.65M
Change in working capital -0.51M 0.67M -1.05M -1.72M -6.66M
Stock based compensation - 0.00M -0.00M -0.31M -6.59M
Other non cash items 8.10M 2.02M -0.24M 14.00M 0.03M
Free cash flow 8.18M 11.41M -0.66M 3.86M 4.59M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
EKF
EKF Diagnostics Holdings Plc		 -0.40
1.61%		 24.40 - 34.97 2.02 1.46 1.72 7.01
SN
Smith & Nephew PLC		 -14.00
1.23%		 1122.50 23.24 12.47 1.70 2.59 2.67 10.76
NIOX
NIOX Group PLC		 2.00
2.99%		 69.00 28.20 18.73 4.84 3.41 4.35 13.85
CREO
Creo Medical Group PLC		 -
-%		 11.25 - - 199.36 0.74 6.21 8.16
AOTI
AOTI Inc		 -1.00
0.77%		 129.00 18.25 8.10 0.64 2.76 0.94 8.31

Profile*

EKF Diagnostics Holdings Plc

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab HbA1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test HbA1c, fully automated hemoglobin A1c analyzer for the monitoring and management of diabetes; and STAT-Site W Beta-Hydroxybutyrate analyzer. In addition, the company offers Creamatocrit Plus, a breast milk analyzer; QuPID and True20 pregnancy tests; Lactate Scout Vet, a handheld lactate analyzer for veterinary care; Hemo Vet, a point-of-care hemoglobin and hematocrit analyzer; Lactate Scout Sport, a lactate analyzer for sports performance; Biosen series for sports; and EKF Link, a data management solution that integrates point-of-care analyzers. Further, it offers Beta-Hydroxybutyrate LiquiColor for monitoring ketosis; RaPET, a range of immunoassay kits; QuStick Strep A for Strep A infection treatment; Hema-Screen Lab Pack for detection of colorectal cancer; PrimeStore MTM, a molecular transport medium that preserves and stabilizes DNA and RNA; Uri-Trak 120M urine analyzer; and clinical chemistry reagents, controls, and standards. Additionally, the company provides precision fermentation, custom bioprocessing, and contract manufacturing solutions; and diagnostic enzymes that include arylacylamidase, beta-hydroxybutyrate dehydrogenase, and salicylate hydroxylase. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

Avon House, Cardiff, United Kingdom, CF64 2EZ

44 29 2071 0570

https://www.ekfdiagnostics.com

297

Name Title Year Born
Mr. David Michael Salter CEO & Exec. Director 1961
Mr. Marc Peter Davies CFO & Director 1980
Mr. Andrew Webb Chief Exec. Officer of Ekf Molecular NA
Mr. Salim Hamir F.C.A. Company Sec. NA
Mr. Julian Huw Baines M.B.E. Executive Chairman 1964
Mr. Stephen Young A.C.M.A. CFO & Executive Director 1963
Mr. Gavin Joseph Jones CEO & Director 1980

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…